QNCX (Quince Therapeutics Inc) קפיטליזציה חשבונאית

Quince Therapeutics is developing the AIDE system for intracellular drug transport via erythrocytes, aiming to capture a significant market share by treating orphan metabolic pathologies. This price chart reflects the asset's quotes, which are currently at -0.04. The absence of regular sales leaves the company dependent on existing reserves and test results, while production capacities are maintained in ideal technical condition.

For the biotech startup Quince Therapeutics (QNCX), whose capital is based on patents for erythrocyte-mediated drug delivery, this metric reflects the current value of all resources minus liabilities. An analysis of the company's net asset book value allows an investor to assess the business's actual asset foundation, separating market speculation from the factual accumulation of liquid and intellectual assets.